Diniz-Freitas M, García-Caballero T, Antúnez-López J, Gándara-Rey J M, García-García A
Oral Surgery Department, School of Dentistry, Santiago de Compostela, Spain.
Oral Dis. 2007 May;13(3):285-90. doi: 10.1111/j.1601-0825.2006.01280.x.
To determine epidermal growth factor receptor (EGFR) expression in oral squamous cell carcinomas (OSCC), and its possible relationships with clinical findings, histological findings, disease course and prognosis.
Surgical specimens of 47 OSCCs were studied immunohistochemically for detection of EGFR using a standardized immunohistochemical detection system (EGFR PharmaDx kit). Statistical analysis was used to investigate possible relationships between EGFR expression and clinical findings, histological findings, cell proliferation (MIB1 labelling index), disease course and patient survival.
Epidermal growth factor receptor expression was absent or weak in 12 cases (25.5%) and moderate or intense in 35 cases (74.5%). However, EGFR expression did not show statistically significant associations with any of the clinical, histological, biological or prognostic variables considered.
First, despite previous suggestions that EGFR is a useful indicator of biological tumour behaviour, the present results suggest that EGFR is not a useful indicator of prognosis in OSCC. Secondly, the high prevalence of EGFR overexpression suggests that the possibility of anti-EGFR therapy in OSCC merits further investigation.
确定口腔鳞状细胞癌（OSCC）中表皮生长因子受体（EGFR）的表达情况，及其与临床检查结果、组织学检查结果、病程和预后的可能关系。
采用标准化免疫组织化学检测系统（EGFR PharmaDx试剂盒），对47例OSCC手术标本进行免疫组织化学研究，以检测EGFR。运用统计学分析来研究EGFR表达与临床检查结果、组织学检查结果、细胞增殖（MIB1标记指数）、病程和患者生存率之间的可能关系。
12例（25.5%）患者的表皮生长因子受体表达缺失或较弱，35例（74.5%）患者的表达为中度或强阳性。然而，EGFR表达与所考虑的任何临床、组织学、生物学或预后变量均无统计学意义上的关联。
首先，尽管此前有观点认为EGFR是肿瘤生物学行为的有用指标，但目前的结果表明，EGFR并非OSCC预后的有用指标。其次，EGFR过表达的高发生率表明，OSCC中抗EGFR治疗的可能性值得进一步研究。
Zotero 插件